Bis-met-histones


FIELD: biotechnology.

SUBSTANCE: nucleic acid molecule encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked through a peptide bond to the mature eukaryotic histone H1. 3. A polypeptide is prepared by culturing a host cell transformed with an expression vector comprising the said nucleic acid molecule. The polypeptide is used as part of a pharmaceutical composition for treatment of cancer, bacterial, viral or fungal infections. Also, the polypeptide is used as part of a composition for diagnosing a patient with respect to the presence of a response to a pharmaceutical composition containing the said polypeptide, or with respect to curability thereof.

EFFECT: invention allows to increase the efficiency of recombinant expression and facilitate the determination of the said polypeptide in the presence of endogenous histones while maintaining biological activity of the mature eukaryotic histone.

16 cl, 3 dwg, 6 tbl, 7 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is presented is a method for the prediction of the postpartum osteopenic syndrome involving studying VDR gene polymorphism Fok-I and predicting the osteopenic syndrome having the genotypes Ff or ff detected. If the genotype FF of the VDR gene polymorphism Fok-I is detected, the VDR gene polymorphism ApaI, BsmI and TaqI are studied additionally. If having at least one of the VDR genotypes AA, Aa ApaI, BB, Bb BsmI and Tt, tt TaqI detected, the postpartum osteopenic syndrome is predicted to develop.

EFFECT: presented method enables predicting the developing postpartum osteopenic syndrome even before the onset of pregnancy, or at any gestational age.

10 ex

FIELD: medicine.

SUBSTANCE: DNA is recovered from peripheral venous blood which is followed by a genetic typing of the APOE gene and detecting polymorphous alleles APOE*2, APOE*3, APOE*4; if the assays shows any genetic types containing alleles APOE*2, a high risk of endometrial cancer is predicted.

EFFECT: invention provides a highly specific criterion for predicting the risk of hyperproliferative diseases of the endometrium, including endometrioid adenocarcinoma in females with hyperplastic processes in the endometrium.

2 dwg, 10 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to a method of diagnosing bipolar affective disorder. The essence of the method consists in the fact that reliable differences in the spectrum of protein distribution in blood serum without proteins albumin, immunoglobulin G, immunoglobulin A, antitrypsin, transferin and haploglobin in patients with endogenic psychosis. If protein spots are detected on electrophoretic gel in areas with the molecular weight of 200, 84, 75, 49, 40 kDa in the patient with endogenic psychosis, bipolar affective disorder is diagnosed.

EFFECT: application of the claimed method makes it possible to increase accuracy in diagnostics being simple in realisation.

2 ex

FIELD: medicine.

SUBSTANCE: method involves determining female serum cytotoxicity to male lymphocytes, including a combined culture with reference male and analysed female serum in a 96-well tray in the presence of the nutrient medium RPMI 1640 in a CO2 incubator. One day later, lymphocytes are counted in the well in a Goryaev's chamber with the male (reference) and female (analysed) serum. That is followed by determining a cytotoxic index (CI), which represents a quotient of the analysed cell count and the reference cell count. The normal cytotoxic index makes approximately 0.7 and less.

EFFECT: invention enables studying the responses of female humoral immune factors to male antigens and evaluating a risk of miscarriage, early spontaneous abortions and missed miscarriages.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine and is intended for the diagnostics of an occlusive affection of vessels in patients with cardiovascular diseases. The age, the level of total homocysteine in blood, the presence of C677T polymorphism mutations in the gene of methyletetrahydrofolate reductase, factor V gene G1691A Leiden mutation, 675 4G/5G polymorphism mutations in the gene of the plasminogen activator inhibitor type I are determined in the patient, after which a value of the discriminant function is calculated by formula. In case of D>0, the presence of the occlusive affection of vessels is diagnosed, if D<0, the absence is diagnosed.

EFFECT: invention provides the effective method for the diagnostics of the occlusive affection of vessels in the patients with cardiovascular diseases.

3 ex

FIELD: medicine.

SUBSTANCE: method includes the determination of an inhibiting impact of a solution of highly-toxic anticholinesterase poison on cholinesterase activity, represented by acetylcholinesterase of human blood erythrocytes, in the presence and in the absence of a substrate, represented by acetylthiocholiniodide. The inhibiting impact of the solution of highly-toxic anticholinesterase poison on the activity of acetylcholinesterase of the human blood erythrocytes is determined first in the presence of the substrate, and then in its absence. An analysed sample is preliminarily diluted by 10 or 100 times to obtain the inhibiting effect on acetylcholinesterase of the human blood erythrocytes in the presence and in the absence of the substrate within 25-75%. After that, the value of the protective effect of acetylthiocholiniodide and the obtained calculated value is compared with table values, determined experimentally in advance for each particular highly-toxic anticholinesterase poison. If the calculated values coincide with the table values, a conclusion about the presence of a respective highly-toxic anticholinesterase poison in the analysed sample is made.

EFFECT: increase of safety.

2 ex

FIELD: medicine.

SUBSTANCE: technique is implemented by biochemical blood analysis followed by determining a diagnostic index by formula: D=X1×K1+X2×K2+X3×K3+X4×K4+const, wherein the values X are described by the biological parameters: X1 is the ceruloplasmin concentration, g/l; X2 is the creatinine concentration, mcmole/l; X3 is the total protein concentration, g/l; X4 is the albumin concentration, g/l; K1, K2, K3; K4 are coefficients: K1=10.4, K2=-0.04, K3=-0.10, K4=0.26, const=-6.84. If D is more than 0, the uncomplicated gestation course is stated with certainty. If D is less than 0, the threatening miscarriage is predicted.

EFFECT: method enables the timely detection of a group of the threatening miscarriage risk, and enables the correct classification.

3 ex

FIELD: medicine.

SUBSTANCE: group of inventions relate to medicine and deals with method of diagnosing neurodegenerative disease in individual, including the following stages (i) determination of one or several parameters, selected from group, consisting of 3ab40 or value of calculated parameter, selected from group, consisting of 2ab40+3ab40, 2ab40+3ab40+2ab42+3ab42 and 1ab40+2ab40+1ab42+2ab42; (ii) comparison of parameter value with standard value, corresponding to value of said parameter in standard sample; and (iii) diagnostics of neurodegenerative disease, in case if increase of parameter value in comparison with standard value is observed. Group of inventions also deals with method of detecting stage, preceding neurodegenerative disease, method of differentiating neurodegenerative disease from stage, preceding said neurodegenerative disease.

EFFECT: group of inventions provide high sensitivity and specificity of detection methods.

13 cl, 12 ex, 14 dwg, 12 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to a method for the prediction of acquired myopia in school children. The substance of the method consists in measuring blood haemoglobin concentrations in 6-8-year-old school children to detect haemoglobin deficiency as shown by the difference of an optimum haemoglobin concentration specific for the above age and an actual haemoglobin concentration in a child. If observing no haemoglobin deficiency at the age of 6-8 years old, a low risk of acquired myopia is predicted. The haemoglobin deficiency to 1.7 g/l enables predicting a risk of acquired low myopia. If the haemoglobin deficiency is 1.7 g/l and more, a high risk of progressive myopia to be developed into moderate or high myopia is predicted.

EFFECT: using the declared method enables developing the reliable and accessible method for the prediction of myopia in the 6-8-year-old children.

2 tbl, 1 dwg, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to method of diagnosing rheumatoid arthritis, method of determining therapeutic agent for treatment of rheumatoid arthritis and set for realisation of methods. Methods are characterised by the fact that include stage of measuring amount of talin in plasma or serum of animal subject. Said measurement is carried out, for instance, by immunologic method with application of antibody, binding with talin. If amount of talin is higher than its average value in control subject without rheumatoid arthritis, rheumatoid arthritis is diagnosed in subject. In case of reduction of talin amount after introduction of therapeutic agent in comparison with amount of talin before introduction, therapeutic effect is stated. Set in accordance with claimed invention contains solid-phase carrier, to which antibody, binding with talin, is attached.

EFFECT: increased efficiency of diagnostics.

9 cl, 4 tbl, 4 ex, 3 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to transfusion medicine, and is applicable in selecting blood plasma donors. That is ensured by sampling blood plasma to be analysed for antimicrobial peptides defensins. If the male defensin titre is from 180 to 545 ng/ml, and the female one is from 128 to 386 ng/ml, a donor is considered to be suitable for blood plasma drawing.

EFFECT: invention enables using the donor plasma in treating the patients suffering from infectious diseases and postoperative, injury and burn complications.

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pediatrics, and can be applied for predicting reduction of child's health level at the age of 12-16. For this purpose an hour after meal and 15 minutes before mouth fluid sampling oral cavity is washed with 0.9% sodium chloride solution. Analysis of child's mouth fluid with determination of ratio of immunoglobulin A concentration to immunoglobulin G concentration is performed. Analysis is carried out twice with difference in 14 days. In case of 1.4 fold and higher reduction of immunoglobulin A concentration to immunoglobulin G concentration ratio during second analysis child is allocated to group of risk of health level reduction.

EFFECT: application of claimed method makes it possible to carry out screening in the process of carrying out prophylactic medical examination to plan health-improving procedures in groups of dispensary observation.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gynaecology, and concerns a method for the prediction of endometrial hyperplasia in the patients with hysteromyoma following uterine artery embolisation (UAE). Substance of the method: all the patients undergo a pre-UEA diagnostic and therapeutic uterine scrapping; 6 months after the UAE, an endometrial pipelle biopsy followed by a pathomorphological study of the biopsy material is conducted. If the study shows no pathology, the biopsy materials are analysed by means of an immune histochemical study using anti-Ki-67 monoclononal antibodies; a percentage of Ki-67 proliferation marker in the uterine gland epithelium (coefficient A) and in the endometrial stroma (coefficient B) is determined; a prognostic index D1 is calculated in initial(pre-UEA) non-atypical hyperplasia, and a prognostic index D2 - in initial (pre-UEA) endometrium in the late proliferation phase: D1=A*0.05-0.74 and D2=B*0.02-0.3. If D1 is 0 or more, recurrent endometrial hyperplasia is predicted, whereas D1 less than 0 enables stating a low risk of recurrent endometrial hyperplasia. If D2 is more than 0, a low risk of developing endometrial hyperplasia is stated, whereas D2 of 0 or less shows developing endometrial hyperplasia.

EFFECT: presented method enables the high-accuracy prediction of the post-UEA endometrial hyperplasia that makes it possible to prescribe the preventive hormone therapy in due time.

4 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to medicine, namely to immunology, and can be applied for detection of contaminants in glucose polymers. For this purpose analysis of inflammatory response is carried out in vitro with application of cell line, which represents cell line of either macrophages or differentiable in macrophages, or cell, expressing one or several toll-like receptors (TLR) or NOD-like receptors, selected from TLR2, TLR4 and NOD2. Analysis contains the following stages: (a) placing macrophages in presence of preparation of glucose polymers, which can contain anti-inflammatory contaminants, and measuring cytokine RANTES production, with production of RANTES cytokine indicating to the fact that preparation contains contaminants capable of initiating inflammatory reaction, and (b) placing cell line, which makes it possible to detect activity of innate immunity receptor or several receptors of innate immunity, selected from TLR2 and NOD2, in presence of preparation and detection of signal of reporter gene, bound to said receptor, with detection of said activity or said signal indicates presence in preparation of contaminant, which represents receptor agonist.

EFFECT: application of claimed method makes it possible to detect contaminants of glucose polymers, and addition of components, such as MDP or LPS, in tested sample makes it possible to act synergistically with contaminants, which increases sensitivity and reduces threshold of detection, with synergetic response being registered for RANTES.

28 cl, 5 ex, 23 dwg, 5 tbl

FIELD: medicine.

SUBSTANCE: peripheral leukocyte blood values before and after a loading test are measured with the use of the gradual submaximal exercise. The method involves the differentiated recovery of different types of leukocytes from the blood to produce a preparation; a total T-cell (Tt) and active T-cell (Ta) count is determined; a Tt/Ta ratio is derived; mononuclear cells are incubated with granulocytes; a granulocyte-binding lymphocyte index (GLI) is determined in accordance with a granulocyte rosette formation (GRL - contact bound to three granulocytes) to granulocyte contact lymphocytes (GCL - contact bound to one granulocyte) ratio in the preparation; leukocyte indices: lymphocyte index (LI), immune reactivity index (IRI), adaptation index, ("CПHP") are determined; immune functional state adaptation coefficients (K) are derived for each value. Total immune functional body state TIFBS is calculated by formula TIFBS = K"спнр"+Kli+Kiri+Kgli+K"итл" before the exercise - TIFBS1 and after the exercise - TIFBS2. A specific immune functional state coefficient SIFSC is calculated by formula SIFSC = (TIFBS1+TIFBS2)/5, and a level of the immune functional SIFSC reserve is determined. If the SIFSC values are above +1.0, the level of the immune functional reserve is considered to be optimal; the SIFSC values falling within the range of 0 to 1.0 show the satisfactory reserve, whereas the SIFSC values below 0 shows the unsatisfactory reserve.

EFFECT: method enables assessing the functional body reserves with the use of combined characteristics including the adaptation body potential, immune reactivity and immune cell interaction.

1 ex

FIELD: medicine.

SUBSTANCE: DNA is recovered from peripheral venous blood. Genetic polymorphisms of tumour necrosis factor α (-308 G/A TNFα), tumour necrosis factor 1 receptor (+36 A/G TNFR1), interferon-inducible T-cell chemoattractant (A/G I-TAC), interleukin 1A (-889 C/T IL-1A), lymphotoxin α (+250 A/G Ltα) are typed by polymerase chain reaction. A high risk of developing hyperplastic processes of endometrium is predicted if detecting a combination of alleles -308 G TNFα, +36 A TNFR1, A I-TAC, -889 T IL-1A and/or a combination of alleles +36 A TNFR1, A I-TAC, -889 T IL-1A and/or a combination of alleles -308 G TNFα,+250 G Ltα, -889 T IL-1A.

EFFECT: higher accuracy.

2 dwg, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: chronic infectious-inflammatory diseases (CIIDs) are diagnosed. Clinical blood analysis and bacteriological tests are conducted. A sensibilisation index (SI) and an immune responsiveness index (IRI) are calculated; total microbial count per 1 m3 of the working space air is measured, and the total microbial number (TMN) is derived. If the TMN is less than 500 CFU/m3 with no CIIDs diagnosed accompanied by the SI of less than 1.08 standard units and the IRI of less than 13 standard units, the immunoassay is considered to be inadvisable. If the TMN falls within the range of 500-2,500 CFU/m3 with one CIID diagnosed accompanied by the SI from 1.08 to 1.3 standard units and the IRI from 13.1 to 15.7 standard units, the immunoassay with the first-level tests seems advisable. Whereas the TMN exceeding 2,500 CFU/m3 with at least two CIIDs accompanied by the SI of 1.4-1.5 standard units and the IRI of 15.8-18.3 standard units, the immunoassay with the second-level tests is thought expedient.

EFFECT: invention enables detecting the workers in need of further examination for the purpose of timely immune correction in the setting of mass routine examinations.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: DNA from peripheral venous blood is extracted. An analysis of a combination of genetic versions of polymorphous markers of genes of cytokines of the gene regulator of the activity of normal expression and secretion of T-cells (-403 G/A RANTES), macrophage protein -1β (+1931 A/T MIP 1β), factor of stromal cells (-801 G/A SDF1), interleukin -1 (-511 C/T IL-1B), monocyte chemoattractant protein -1 (C/G MCP-1), interleukin -4 (-590 C/T IL-4) is performed. An increased risk of development of a combination of uterine myoma with endometriosis and hyperplastic processes of the endometrium is predicted if the combination of alleles 403 A RANTES, G MCP-1,+1931 A MIP 1β, -590 C IL-4 or the combination of alleles -403 A RANTES,+1931 A MIP 1β, -801 G SDF1, -511 C IL-1B is identified.

EFFECT: application of the claimed method makes it possible to detect a group of patients with a risk of developing a combination of proliferative reproductive system diseases, which makes it possible to prescribe an adequate therapy to prevent further progressing of the diseases.

3 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention deals with method of predicting level of arterial pressure in women of Russian nationality, born in Central Black Earth region of Russia. Method includes separation of DNA from lymphocytes of peripheral venous blood and analysis of genetic polymorphisms. +46G/A ADRB2 and 4a/4b eNOS by method of polymerase chain reaction Level of systolic arterial pressure in women in late pregnancy is predicted by results of multiple regression equation of the following type: Y1=15,455+2,544x1+9,946x2+0,736x3+4,716x4+0,185x5, where x1 is genetic variant in locus - 4a/4b eNOS, namely 4b4b=1; 4a4b=2; 4a4a=3; x2 is presence of preeclampsia in relatives: yes=0, no=1; x3 is level of systolic arterial pressure before pregnancy, mm Hg; x4 is presence of cardiovascular system pathology: yes=0, no=1; x5 is woman's weight before pregnancy, kg Level of diastolic arterial pressure in women in late pregnancy is predicted, for which purpose multiple regression equation of the following type is used: Y2=14,200+7,768x1-2,877x2+7,500x3+0,414x4+3,668x5, where x1 is genetic variant in locus - 4a4b eNOS, namely 4b4b+4a4b=1, 4a4a=0; x2 is genetic variant in locus +46G/A ADRB2, namely GG+GA=1, AA=0; x3 is presence of preeclapsia in relatives:yes=0, no=1; x4 is systolic arterial pressure before pregnancy, mm Hg; x5 is presence of cardiovascular system pathology: yes=0, no=1.

EFFECT: invention makes it possible to realise early prediction of increase of arterial pressure level in women in late pregnancy, will make it possible to form of women at the stage of pregravidal preparation and at early terms of pregnancy groups of high risk of developing hypertension in late pregnancy, as well as realise required therapeutic-preventive measures aimed at prevention of development of said pregnancy complication in due time.

2 dwg, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method is based on contacting a membrane test strip with an analysed fluid sample and initiating thereby a motion along the test strip membranes of reagents being parts of the sample or coating the membrane, and forming the immune complexes to be detected in the course of reactions in the membrane pores or on the surface thereof. A distinguishing feature of the presented method for antigen detection is that the test strip is coated additionally within the test sample contact area with a certain amount of specific antibodies, which react to the detected antigen expected to be found in the sample, when a fluid front moves and block a certain number of binding sites. The number of the coating free antibodies is specified so that the low content thereof in the analysed sample being of no diagnostic importance ensures blocking the binding sites completely that prevents the antigen from binding in the analysed area of the test strip and from developing a destructive staining in the analysed area.

EFFECT: presented approach enables reliable diagnosing based on the detection results of the antigens of gastrointestinal disorders, avoiding the achievement of positive test results for the low-antigen samples, which testifies to no development of the disease in an individual.

1 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: method includes treating a sample with a denaturing buffer solution, sorbing short RNA on a fibre glass sorbent in the presence of a chaotropic agent, followed by washing off non-bonded biopolymers and chemical reagents from the sorbent and eluting the end product. The biological fluid sample undergoes two-step denaturing, wherein at the first step two volumes of the denaturing buffer solution are added to the sample and at the second step two volumes of 96% ethanol and equal volume of chloroform are added to the obtained mixture, followed by stirring and separating the residue by centrifuging. Non-bonded biopolymers are washed off from the sorbent twice with the buffer solution and elution of the end product from the sorbent is carried out with the buffer solution.

EFFECT: simple method, short duration of the method and high output of short RNA.

3 cl, 3 tbl, 4 ex

Up!